检索结果 - Karim Iskander

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes

    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes 由 Ola Landgren, Karim Iskander

    出版 2017
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53

    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53 由 Xing Gong, Labanyamoy Kole, Karim Iskander, Anil K. Jaiswal

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity

    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity 由 Karim Iskander, Jessica Li, Shuhua Han, Biao Zheng, Anil K. Jaiswal

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma 由 Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity

    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity 由 Delwin J. Long, Karim Iskander, Amos Gaikwad, Meral J. Arin, Dennis R. Roop, Richard J. Knox, Roberto Barrios, Anil K. Jaiswal

    出版 2002
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types 由 Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR 由 Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials 由 Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, José Banchs, Roman Hájek, John D. Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim Iskander, Daniel J. Lenihan

    出版 2018
    获取全文
    Revisão
    加到收藏夹
    Saved in:

检索工具: